Aytu BioPharma Inc./$AYTU
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Ticker
$AYTU
Sector
Primary listing
Employees
83
Headquarters
Website
AYTU Metrics
BasicAdvanced
$25M
-
-$1.92
0.29
-
Price and volume
Market cap
$25M
Beta
0.29
52-week high
$2.82
52-week low
$0.95
Average daily volume
77K
Financial strength
Current ratio
1.229
Quick ratio
0.998
Long term debt to equity
49.502
Total debt to equity
122.576
Interest coverage (TTM)
0.37%
Profitability
EBITDA (TTM)
6.025
Gross margin (TTM)
67.56%
Net profit margin (TTM)
-20.52%
Operating margin (TTM)
1.85%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
0.61%
Return on equity (TTM)
-50.23%
Valuation
Price to revenue (TTM)
0.276
Price to book
1.06
Price to tangible book (TTM)
-1.34
Price to free cash flow (TTM)
-3.947
Free cash flow yield (TTM)
-25.33%
Free cash flow per share (TTM)
-0.626
Growth
Revenue change (TTM)
-0.38%
Earnings per share change (TTM)
19.18%
3-year revenue growth (CAGR)
-14.64%
10-year revenue growth (CAGR)
56.52%
3-year earnings per share growth (CAGR)
-65.29%
AYTU News
AllArticlesVideos
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
Accesswire·24 hours ago
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
Accesswire·4 days ago
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aytu BioPharma Inc. stock?
Aytu BioPharma Inc. (AYTU) has a market cap of $25M as of December 19, 2025.
What is the P/E ratio for Aytu BioPharma Inc. stock?
The price to earnings (P/E) ratio for Aytu BioPharma Inc. (AYTU) stock is 0 as of December 19, 2025.
Does Aytu BioPharma Inc. stock pay dividends?
No, Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next Aytu BioPharma Inc. dividend payment date?
Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders.
What is the beta indicator for Aytu BioPharma Inc.?
Aytu BioPharma Inc. (AYTU) has a beta rating of 0.29. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.